Cue Biopharma, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value
Cue Biopharma, Inc. (CUE) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value of $0.72 per share for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue · last filed 2025-11-12
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for the quarter ending 2025-09-30 was $0.72, a 4.35% increase year-over-year.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for the quarter ending 2025-06-30 was $0.62, a 62.42% decline year-over-year.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for the quarter ending 2024-09-30 was $0.69, a 83.45% decline year-over-year.
- Cue Biopharma, Inc. share-based compensation arrangement by share-based payment award, options, nonvested options forfeited, weighted average grant date fair value for the quarter ending 2024-06-30 was $1.65, a 56.00% decline year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value 9 month |
|---|---|---|---|
| 2025-09-30 | $0.72 10-Q · filed 2025-11-12 | $0.82 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $0.62 10-Q · filed 2025-08-12 | $0.99 10-Q · filed 2025-08-12 | |
| 2024-09-30 | $0.69 10-Q · filed 2025-11-12 | $1.42 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $1.65 10-Q · filed 2025-08-12 | $1.93 10-Q · filed 2025-08-12 | |
| 2023-09-30 | $4.17 10-Q · filed 2024-11-14 | $3.65 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $3.75 10-Q · filed 2024-08-14 | $3.25 10-Q · filed 2024-08-14 | |
| 2023-03-31 | $3.20 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |